Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 3Gastrointestinal 3Other solid neoplasm 2Head & Neck 2Tumor-Agnostic 1Sarcoma 1Other hematologic neoplasm 1Endocrine 1Dermatologic 1Breast 1

Conditions

Thyroid Cancer, Papillary 1Neoplasms 1Melanoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 100Nivolumab 69Cyclophosphamide 67Ipilimumab 66fludarabine 34aldesleukin 29fludarabine phosphate 28Vemurafenib 28Interleukin-2 26trametinib 20Biopsy 20dabrafenib 17Radiotherapy 16Temozolomide 15Cisplatin 15Magnetic Resonance Spectroscopy 14Gemcitabine 14Filgrastim 14atezolizumab 13Specimen Handling 13Carboplatin 13CTLA-4 Antigen 13spartalizumab 12romidepsin 12Paclitaxel 12Bortezomib 11poly ICLC 10cobimetinib 10Peripheral Blood Stem Cell Transplantation 10Oxaliplatin 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Famotidine × Dermatologic × Clear all
NCT00451880 2011-10-13

Study of XL281 in Adults With Solid Tumors

Exelixis

Phase 1 Completed
180 enrolled
DermatologicEndocrineGastrointestinalHead & NeckThoracic

Thyroid Cancer, Papillary, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡